Literature DB >> 21440664

The application of next-generation sequencing technologies to drug discovery and development.

Peter M Woollard1, Nalini A L Mehta, Jessica J Vamathevan, Stephanie Van Horn, Bhushan K Bonde, David J Dow.   

Abstract

Next-generation sequencing (NGS) technologies represent a paradigm shift in sequencing capability. The technology has already been extensively applied to biological research, resulting in significant and remarkable insights into the molecular biology of cells. In this review, we focus on current and potential applications of the technology as applied to the drug discovery and development process. Early applications have focused on the oncology and infectious disease therapeutic areas, with emerging use in biopharmaceutical development and vaccine production in evidence. Although this technology has great potential, significant challenges remain, particularly around the storage, transfer and analysis of the substantial data sets generated.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21440664     DOI: 10.1016/j.drudis.2011.03.006

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  9 in total

1.  1,8-Naphthyridine-2,7-diamine: a potential universal reader of Watson-Crick base pairs for DNA sequencing by electron tunneling.

Authors:  Feng Liang; Stuart Lindsay; Peiming Zhang
Journal:  Org Biomol Chem       Date:  2012-11-21       Impact factor: 3.876

Review 2.  PathoQC: Computationally Efficient Read Preprocessing and Quality Control for High-Throughput Sequencing Data Sets.

Authors:  Changjin Hong; Solaiappan Manimaran; William Evan Johnson
Journal:  Cancer Inform       Date:  2015-05-12

Review 3.  Towards personalized medicine mediated by in vitro virus-based interactome approaches.

Authors:  Hiroyuki Ohashi; Etsuko Miyamoto-Sato
Journal:  Int J Mol Sci       Date:  2014-04-21       Impact factor: 5.923

4.  The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains.

Authors:  Mohammad Alzrigat; Alba Atienza Párraga; Muntasir Mamun Majumder; Anqi Ma; Jian Jin; Anders Österborg; Hareth Nahi; Kenneth Nilsson; Caroline A Heckman; Fredrik Öberg; Antonia Kalushkova; Helena Jernberg-Wiklund
Journal:  Oncotarget       Date:  2017-10-20

5.  Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis.

Authors:  Zhonghai Guan; Huanrong Lan; Xiangheng Chen; Xiaoxia Jiang; Xuanwei Wang; Ketao Jin
Journal:  Mol Med Rep       Date:  2017-08-10       Impact factor: 2.952

6.  Data- and expert-driven rule induction and filtering framework for functional interpretation and description of gene sets.

Authors:  Aleksandra Gruca; Marek Sikora
Journal:  J Biomed Semantics       Date:  2017-06-26

7.  A potential novel therapy for FGFR1-amplified pancreatic cancer with bone metastasis, screened by next-generation sequencing and a patient-derived xenograft model.

Authors:  Zhonghai Guan; Huanrong Lan; Dan Sun; Xuanwei Wang; Ketao Jin
Journal:  Oncol Lett       Date:  2018-12-28       Impact factor: 2.967

Review 8.  Next-generation sequencing in veterinary medicine: how can the massive amount of information arising from high-throughput technologies improve diagnosis, control, and management of infectious diseases?

Authors:  Steven Van Borm; Sándor Belák; Graham Freimanis; Alice Fusaro; Fredrik Granberg; Dirk Höper; Donald P King; Isabella Monne; Richard Orton; Toon Rosseel
Journal:  Methods Mol Biol       Date:  2015

Review 9.  Therapeutic roles of natural remedies in combating hereditary ataxia: A systematic review.

Authors:  Michael Weng Lok Phang; Sze Yuen Lew; Ivy Chung; William Kiong-Seng Lim; Lee Wei Lim; Kah Hui Wong
Journal:  Chin Med       Date:  2021-01-28       Impact factor: 5.455

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.